These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9326215)

  • 21. New approaches to management of bleeding disorders.
    Aledort LM
    Hosp Pract (Off Ed); 1989 Feb; 24(2):207-11, 214, 219-21 passim. PubMed ID: 2493009
    [No Abstract]   [Full Text] [Related]  

  • 22. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease.
    Mannucci PM; Canciani MT; Rota L; Donovan BS
    Br J Haematol; 1981 Feb; 47(2):283-93. PubMed ID: 6781527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of hemophilia A and von Willebrand's disease with 1-deamino-8-D-arginine vasopressin (DDAVP). Hemophilia and DDAVP].
    Ingerslev J; Christiansen SE; Kristensen T; Wallevik K; Bernvil SS
    Ugeskr Laeger; 1985 Nov; 147(45):3592-4. PubMed ID: 3907076
    [No Abstract]   [Full Text] [Related]  

  • 24. [DDAVP: alternative therapy in moderate pathology of Factor VIII/von Willebrand].
    Vicente V; Alberca I; Moraleda JM; López Borrasca A
    Sangre (Barc); 1983; 28(4):531-2. PubMed ID: 6606856
    [No Abstract]   [Full Text] [Related]  

  • 25. How I treat patients with von Willebrand disease.
    Mannucci PM
    Blood; 2001 Apr; 97(7):1915-9. PubMed ID: 11264151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment protocol of haemophilia and other congenital bleeding disorders in Italy. Italian Association of Hemophilia Centers (AICE).
    Gringeri A
    Haemophilia; 1998 Jul; 4(4):423-4. PubMed ID: 9873767
    [No Abstract]   [Full Text] [Related]  

  • 27. The clinical significance of different routes of desmopressin (DDAVP) administration in various bleeding disorders.
    Mörsdorf S; Köhler M; Leipnitz G; Wenzel E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):503-7. PubMed ID: 2465962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. D.D.A.V.P. in haemophilia.
    Lancet; 1977 Apr; 1(8017):889-90. PubMed ID: 67293
    [No Abstract]   [Full Text] [Related]  

  • 29. DDAVP--the multipotent drug in patients with coagulopathies.
    Schulman S
    Transfus Med Rev; 1991 Apr; 5(2):132-44. PubMed ID: 1821643
    [No Abstract]   [Full Text] [Related]  

  • 30. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of hemophilia A and von Willebrand's disease patients with an intranasal dripping of DDAVP.
    Kobayashi I
    Thromb Res; 1979; 16(5-6):775-9. PubMed ID: 316584
    [No Abstract]   [Full Text] [Related]  

  • 32. Regulated release of VWF and FVIII and the biologic implications.
    Haberichter SL; Shi Q; Montgomery RR
    Pediatr Blood Cancer; 2006 May; 46(5):547-53. PubMed ID: 16470522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra-platelet von Willebrand factor.
    Rodeghiero F; Castaman G; Di Bona E; Ruggeri M; Lombardi R; Mannucci PM
    Eur J Haematol; 1988 Feb; 40(2):163-7. PubMed ID: 3126081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety.
    Lethagen S
    Semin Thromb Hemost; 2003 Feb; 29(1):101-6. PubMed ID: 12640572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with deamino-8-D-AGR-Vasopressin (DDAVP) in patients with Factor VIII deficiency.
    Sweeney JD; Crosby P; McCann SR; Temperley IJ
    Ir J Med Sci; 1981 Aug; 150(8):236-9. PubMed ID: 6974718
    [No Abstract]   [Full Text] [Related]  

  • 37. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.
    Ruggeri ZM; Mannucci PM; Lombardi R; Federici AB; Zimmerman TS
    Blood; 1982 Jun; 59(6):1272-8. PubMed ID: 6805532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Desmopressin in the treatment of bleeding disorders].
    Tomasiak MM; Tomasiak M; Bodzenta-Lukaszyk A
    Pol Arch Med Wewn; 2005 May; 113(5):509-15. PubMed ID: 16479837
    [No Abstract]   [Full Text] [Related]  

  • 39. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.
    Leissinger C; Becton D; Cornell C; Cox Gill J
    Haemophilia; 2001 May; 7(3):258-66. PubMed ID: 11380629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hemostatic effect of deamino-8-D-arginine vasopressin (DDAVP) in hemophilia A and von Willebrand's disease].
    Fukui H; Takase T
    Rinsho Ketsueki; 1985 Jul; 26(7):1069-79. PubMed ID: 3932720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.